marketcaparena
Search

    LH

    LABCORP HOLDINGS INC.

    Company overview

    Market capitalization
    $25.11B
    Employees
    71,000
    Latest publication
    2026-09-29
    About LABCORP HOLDINGS INC.

    Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue3,731,100,000USD3,537,600,000USD3,520,000,000USD3,563,500,000USD3,527,300,000USD3,345,100,000USD3,330,000,000USD3,282,000,000USD
    Cost Of Revenue2,619,100,000USD2,523,800,000USD—2,538,400,000USD2,481,100,000USD2,397,100,000USD2,433,100,000USD2,377,600,000USD
    Gross Profit1,112,000,000USD1,013,800,000USD993,200,000USD1,025,100,000USD1,046,200,000USD948,000,000USD896,300,000USD904,400,000USD
    Selling General Administrative577,200,000USD551,000,000USD—552,400,000USD579,300,000USD546,000,000USD595,200,000USD568,600,000USD
    Total Operating Expenses660,400,000USD633,000,000USD—628,500,000USD651,700,000USD622,000,000USD—650,300,000USD
    Operating Income451,600,000USD380,800,000USD267,600,000,000USD396,600,000USD394,500,000USD326,000,000USD216,500,000,000USD254,100,000USD
    Total Other Income Expense Net-59,000,000USD-56,000,000USD—-54,400,000USD-88,100,000USD-50,500,000USD—-43,000,000USD
    Interest Expense61,100,000USD55,100,000USD—56,000,000USD57,100,000USD56,000,000USD-63,400,000USD50,400,000USD
    Income Before Tax392,600,000USD324,800,000USD—342,200,000USD306,400,000USD275,500,000USD183,800,000USD211,100,000USD
    Income Tax Expense87,300,000USD41,700,000USD25,700,000USD75,500,000USD66,400,000USD62,200,000USD40,200,000USD41,000,000USD
    Equity Method Income Loss-6,200,000USD-5,100,000USD—-5,200,000USD-1,700,000USD-300,000USD-700,000USD-500,000USD
    Net Income299,100,000USD278,000,000USD164,700,000USD261,500,000USD238,300,000USD213,000,000USD143,400,000USD169,600,000USD
    Minority Interest400,000USD200,000USD—400,000USD400,000USD200,000USD—300,000USD
    Net Income Applicable To Common Shares298,700,000USD277,800,000USD—261,100,000USD237,900,000USD212,800,000USD—169,300,000USD
    Discontinued Operations———————0USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinal

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue13,951,700,000USD13,008,900,000USD12,161,600,000USD14,876,800,000USD16,120,900,000USD13,978,500,000USD11,554,800,000USD11,333,400,000USD
    Cost Of Revenue9,939,200,000USD9,384,500,000USD8,796,700,000USD10,491,700,000USD10,496,600,000USD9,025,700,000USD8,302,300,000USD8,157,000,000USD
    Gross Profit4,012,500,000USD3,624,400,000USD3,364,900,000USD4,385,100,000USD5,624,300,000USD4,952,800,000USD3,252,500,000USD3,176,400,000USD
    Selling General Administrative2,216,300,000USD2,230,000,000USD2,021,400,000USD1,996,600,000USD1,952,100,000USD1,729,300,000USD1,624,500,000USD1,570,900,000USD
    Total Operating Expenses2,627,800,000USD2,537,700,000USD2,639,300,000USD2,611,200,000USD2,364,800,000USD2,507,400,000USD1,922,300,000USD1,802,600,000USD
    Operating Income1,384,700,000USD1,086,700,000USD725,600,000USD1,773,900,000USD3,259,500,000USD2,445,400,000USD1,330,200,000USD1,325,700,000USD
    Total Other Income Expense Net-263,900,000USD-125,800,000USD-155,300,000USD-196,700,000USD-159,400,000USD-229,200,000USD-235,100,000USD-57,400,000USD
    Interest Expense224,100,000USD208,300,000USD199,600,000USD180,300,000USD212,100,000USD207,400,000USD240,700,000USD244,200,000USD
    Income Before Tax1,120,800,000USD960,900,000USD570,300,000USD1,577,200,000USD3,100,100,000USD2,216,200,000USD1,095,100,000USD1,268,300,000USD
    Income Tax Expense229,800,000USD212,400,000USD188,500,000USD302,000,000USD747,100,000USD662,100,000USD280,000,000USD384,400,000USD
    Equity Method Income Loss-13,300,000USD-1,400,000USD-1,400,000USD5,400,000USD26,500,000USD2,900,000USD9,800,000USD—
    Discontinued Operations0USD0USD38,800,000USD—————
    Net Income877,700,000USD747,100,000USD419,200,000USD1,280,600,000USD2,379,500,000USD1,557,000,000USD824,900,000USD883,700,000USD
    Minority Interest1,200,000USD1,100,000USD1,200,000USD1,500,000USD2,200,000USD900,000USD1,100,000USD200,000USD
    Net Income Applicable To Common Shares876,500,000USD746,000,000USD418,000,000USD1,279,100,000USD2,377,300,000USD1,556,100,000USD823,800,000USD883,700,000USD
    Research Development———————0USD
    Unclassified Operating Expenses———————231,700,000USD
    Interest Income———————225,100,000USD
    Net Interest Income———————-244,200,000USD
    Tax Provision———————384,400,000USD
    Net Income From Continuing Ops———————883,900,000USD
    Ebit———————1,512,500,000USD
    Ebitda———————2,064,600,000USD
    Depreciation And Amortization———————552,100,000USD
    Reconciled Depreciation———————552,100,000USD
    Non Operating Income Net Other———————186,800,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets18,532,300,000USD19,087,100,000USD18,392,700,000USD18,261,600,000USD18,059,900,000USD17,603,800,000USD18,379,000,000USD18,612,500,000USD
    Cash And Equivalents141,800,000USD981,100,000USD532,300,000USD598,100,000USD647,300,000USD369,400,000USD1,518,700,000USD1,517,300,000USD
    Total Current Assets3,814,900,000USD4,558,800,000USD4,020,500,000USD4,078,800,000USD4,087,200,000USD3,789,700,000USD4,806,500,000USD4,909,900,000USD
    Other Current Assets606,100,000USD629,500,000USD692,800,000USD—————
    Other Non Current Assets769,300,000USD724,900,000USD751,300,000USD648,100,000USD633,000,000USD647,000,000USD652,200,000USD612,600,000USD
    Total Liabilities9,909,100,000USD10,341,600,000USD9,756,000,000USD9,548,600,000USD9,570,500,000USD9,282,100,000USD10,312,500,000USD10,427,100,000USD
    Total Current Liabilities2,124,600,000USD2,641,000,000USD2,823,500,000USD2,629,200,000USD2,716,800,000USD2,064,600,000USD3,330,200,000USD3,412,000,000USD
    Other Current Liabilities862,400,000USD851,900,000USD847,800,000USD878,000,000USD835,800,000USD770,400,000USD871,200,000USD757,500,000USD
    Other Non Current Liabilities717,600,000USD691,800,000USD647,800,000USD639,100,000USD643,200,000USD497,900,000USD517,400,000USD528,200,000USD
    Total Stockholder Equity8,606,800,000USD8,728,600,000USD8,619,800,000USD8,696,900,000USD8,472,700,000USD8,307,400,000USD8,052,200,000USD8,170,200,000USD
    Total Equity Including Noncontrolling Interest8,623,200,000USD8,745,500,000USD8,636,700,000USD8,713,000,000USD8,489,400,000USD8,321,700,000USD8,066,500,000USD8,185,400,000USD
    Short Long Term Debt1,800,000USD1,000,800,000USD1,000,200,000USD—————
    Long Term Debt5,857,600,000USD5,833,700,000USD5,084,600,000USD5,082,500,000USD5,077,300,000USD5,568,700,000USD5,331,200,000USD5,352,100,000USD
    Deferred Revenue387,800,000USD405,200,000USD439,100,000USD391,600,000USD398,000,000USD388,300,000USD392,200,000USD403,100,000USD
    Net Receivables2,342,400,000USD2,288,600,000USD2,103,800,000USD2,109,100,000USD2,120,600,000USD2,123,200,000USD1,944,100,000USD2,058,500,000USD
    Inventory562,200,000USD497,700,000USD534,700,000USD521,500,000USD508,100,000USD488,300,000USD493,200,000USD483,100,000USD
    Property Plant Equipment Net3,100,500,000USD3,065,500,000USD3,885,400,000USD3,112,800,000USD3,133,800,000USD3,090,800,000USD3,829,900,000USD3,050,000,000USD
    Goodwill7,030,100,000USD6,955,200,000USD6,789,500,000USD6,682,300,000USD6,551,100,000USD6,421,100,000USD6,369,700,000USD6,482,400,000USD
    Intangible Assets3,678,200,000USD3,636,100,000USD3,596,000,000USD3,571,400,000USD3,494,400,000USD3,487,200,000USD3,488,900,000USD3,540,700,000USD
    Accounts Payable688,500,000USD695,700,000USD840,800,000USD668,500,000USD793,000,000USD717,900,000USD875,800,000USD660,900,000USD
    Short Term Debt180,300,000USD183,200,000USD191,100,000USD186,700,000USD186,100,000USD182,800,000USD1,000,300,000USD184,300,000USD
    Common Stock7,300,000USD7,400,000USD7,500,000USD7,500,000USD7,500,000USD7,600,000USD7,600,000USD7,600,000USD
    Retained Earnings8,701,400,000USD8,784,400,000USD8,639,900,000USD8,698,400,000USD8,498,000,000USD8,455,600,000USD8,303,400,000USD8,275,800,000USD
    Accumulated Other Comprehensive Income-101,900,000USD-63,200,000USD-27,600,000USD-42,000,000USD-34,600,000USD-191,600,000USD-261,600,000USD-113,200,000USD
    Cash And Short Term Investments141,800,000USD———————
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets18,392,700,000USD18,379,000,000USD16,725,100,000USD20,155,100,000USD20,385,400,000USD20,071,700,000USD18,046,400,000USD16,185,300,000USD
    Cash And Equivalents532,300,000USD1,518,700,000USD536,800,000USD430,000,000USD1,472,700,000USD1,320,800,000USD337,500,000USD426,800,000USD
    Total Current Assets4,020,500,000USD4,806,500,000USD3,765,400,000USD4,625,000,000USD5,330,500,000USD5,125,400,000USD2,981,200,000USD2,835,400,000USD
    Other Current Assets692,800,000USD——————309,000,000USD
    Other Non Current Assets751,300,000USD652,200,000USD536,500,000USD432,700,000USD462,600,000USD410,000,000USD435,400,000USD—
    Total Liabilities9,756,000,000USD10,312,500,000USD8,834,600,000USD10,039,600,000USD10,091,400,000USD10,691,300,000USD10,459,300,000USD—
    Total Current Liabilities2,823,500,000USD3,330,200,000USD3,225,200,000USD3,078,500,000USD2,782,900,000USD3,078,500,000USD2,655,800,000USD1,878,900,000USD
    Other Current Liabilities847,800,000USD871,200,000USD804,000,000USD1,068,800,000USD1,404,100,000USD1,357,700,000USD942,400,000USD—
    Other Non Current Liabilities647,800,000USD517,400,000USD409,300,000USD422,800,000USD402,000,000USD526,400,000USD383,200,000USD—
    Total Stockholder Equity8,619,800,000USD8,052,200,000USD7,875,000,000USD10,096,600,000USD10,273,400,000USD9,359,700,000USD7,567,000,000USD6,971,400,000USD
    Total Equity Including Noncontrolling Interest8,636,700,000USD8,066,500,000USD7,890,500,000USD10,115,500,000USD10,294,000,000USD9,380,400,000USD7,587,100,000USD—
    Short Long Term Debt1,000,200,000USD——————10,000,000USD
    Long Term Debt5,084,600,000USD5,331,200,000USD4,054,700,000USD5,038,800,000USD5,416,500,000USD5,419,000,000USD5,789,800,000USD6,041,900,000USD
    Deferred Revenue439,100,000USD392,200,000USD421,700,000USD582,100,000USD558,500,000USD506,500,000USD451,000,000USD—
    Net Receivables2,103,800,000USD1,944,100,000USD1,913,300,000USD2,222,000,000USD2,261,500,000USD2,479,800,000USD1,543,900,000USD1,862,300,000USD
    Inventory534,700,000USD493,200,000USD474,600,000USD470,600,000USD401,400,000USD423,200,000USD244,700,000USD237,300,000USD
    Property Plant Equipment Net3,885,400,000USD3,829,900,000USD3,648,900,000USD3,729,800,000USD3,561,700,000USD3,519,400,000USD3,369,400,000USD1,784,700,000USD
    Goodwill6,789,500,000USD6,369,700,000USD6,142,500,000USD8,121,000,000USD7,958,900,000USD7,751,500,000USD7,865,000,000USD—
    Intangible Assets3,596,000,000USD3,488,900,000USD3,342,000,000USD3,946,900,000USD3,735,500,000USD3,961,100,000USD4,034,500,000USD3,911,100,000USD
    Accounts Payable840,800,000USD875,800,000USD827,500,000USD934,800,000USD621,300,000USD638,900,000USD632,300,000USD634,600,000USD
    Short Term Debt191,100,000USD1,000,300,000USD999,800,000USD301,300,000USD1,500,000USD376,700,000USD415,200,000USD17,900,000USD
    Common Stock7,500,000USD7,600,000USD7,700,000USD8,100,000USD8,500,000USD9,000,000USD9,000,000USD11,700,000USD
    Retained Earnings8,639,900,000USD8,303,400,000USD7,888,200,000USD10,581,700,000USD10,456,800,000USD9,402,300,000USD7,903,600,000USD7,079,800,000USD
    Accumulated Other Comprehensive Income-27,600,000USD-261,600,000USD-59,300,000USD-493,200,000USD-191,900,000USD-161,900,000USD-372,400,000USD-463,100,000USD
    Cash And Short Term Investments————1,483,600,000USD—346,600,000USD426,800,000USD
    Short Term Investments————10,900,000USD—9,100,000USD—
    Total Liab———————9,194,800,000USD
    Deferred Long Term Liab———————940,000,000USD
    Other Current Liab———————745,200,000USD
    Capital Stock———————11,700,000USD
    Other Liab———————1,274,000,000USD
    Good Will———————7,360,300,000USD
    Other Assets———————277,700,000USD
    Cash———————426,800,000USD
    Current Deferred Revenue———————356,400,000USD
    Net Debt———————5,633,000,000USD
    Short Long Term Debt Total———————6,059,800,000USD
    Long Term Investments———————60,500,000USD
    Property Plant Equipment Gross———————1,784,700,000USD
    Treasury Stock———————-1,108,100,000USD
    Common Stock Shares Outstanding———————102,600,000shares
    Non Current Assets Total———————13,349,900,000USD
    Non Current Liabilities Total———————7,315,900,000USD
    Non Current Liabilities Other———————334,000,000USD
    Non Currrent Assets Other———————276,000,000USD
    Net Working Capital———————956,500,000USD
    Net Tangible Assets———————-4,300,000,000USD
    Unclassified Non Current Assets———————-320,400,000USD
    Unclassified Current Liabilities———————114,800,000USD
    Unclassified Non Current Liabilities———————-1,274,000,000USD
    Unclassified Equity———————1,439,400,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ3 20232023-09-30 · USDQ1 20232023-06-30 · USDQ3 20222022-09-30 · USD
    Depreciation352,300,000USD508,100,000USD337,100,000USD472,900,000USD311,400,000USD430,900,000USD285,000,000USD477,700,000USD
    Stock Based Compensation66,600,000USD96,100,000USD66,900,000USD89,400,000USD62,400,000USD101,700,000USD67,300,000USD113,900,000USD
    Change To Account Receivables-247,100,000USD-130,400,000USD-139,900,000USD-143,200,000USD-192,200,000USD-173,600,000USD-107,600,000USD51,800,000USD
    Change To Inventory-29,700,000USD-17,900,000USD-3,500,000USD2,000,000USD27,700,000USD9,700,000USD-16,100,000USD-47,500,000USD
    Change To Liabilities-201,800,000USD-427,400,000USD-260,000,000USD-297,700,000USD-218,100,000USD-501,800,000USD-433,100,000USD-382,100,000USD
    Change In Working Capital-449,800,000USD-349,500,000USD-174,900,000USD-347,100,000USD-225,400,000USD-376,700,000USD-279,400,000USD60,900,000USD
    Operating Cash Flow637,000,000USD1,026,300,000USD639,100,000USD808,600,000USD531,300,000USD748,100,000USD472,600,000USD1,302,300,000USD
    Capital Expenditures-252,600,000USD-310,600,000USD-203,900,000USD-377,800,000USD-262,000,000USD-286,400,000USD-181,500,000USD-364,000,000USD
    Net Investments-17,500,000USD-179,900,000USD-172,000,000USD—————
    Other Investing Activities-427,900,000USD-324,000,000USD-63,500,000USD-751,200,000USD-293,100,000USD-516,700,000USD-136,900,000USD-1,013,600,000USD
    Unclassified Investing Cash Flow9,700,000USD10,400,000USD9,300,000USD-28,200,000USD-23,000,000USD-37,800,000USD-34,900,000USD-1,300,000USD
    Investing Cash Flow-688,300,000USD-804,100,000USD-430,100,000USD-1,157,200,000USD-578,100,000USD-840,900,000USD-353,300,000USD-1,378,900,000USD
    Net Common Stock Issuance-497,900,000USD-255,600,000USD-229,000,000USD-213,700,000USD-137,800,000USD-1,048,600,000USD-38,700,000USD-844,600,000USD
    Common Dividends Paid-119,900,000USD-181,400,000USD-121,500,000USD-183,000,000USD-122,500,000USD-192,900,000USD-129,000,000USD-131,600,000USD
    Other Financing Activities-31,300,000USD-8,900,000USD-7,300,000USD—————
    Unclassified Financing Cash Flow309,700,000USD-720,700,000USD-749,300,000USD1,723,300,000USD38,600,000USD1,628,700,000USD1,652,100,000USD26,600,000USD
    Financing Cash Flow-339,400,000USD-1,166,600,000USD-1,107,100,000USD1,326,600,000USD-221,700,000USD387,200,000USD1,484,400,000USD-949,600,000USD
    Effect Of Forex Changes On Cash200,000USD23,800,000USD26,700,000USD2,500,000USD-3,200,000USD3,500,000USD6,300,000USD-36,600,000USD
    Change In Cash-390,500,000USD-920,600,000USD-871,400,000USD980,500,000USD-271,700,000USD297,900,000USD1,610,000,000USD-1,062,800,000USD
    Deferred Income Tax—76,400,000USD-12,200,000USD-58,600,000USD-39,100,000USD-18,200,000USD16,200,000USD-51,600,000USD
    End Cash Flow—598,100,000USD647,300,000USD1,517,300,000USD265,100,000USD727,900,000USD1,930,600,000USD409,900,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Depreciation179,000,000USD173,300,000USD173,000,000USD171,000,000USD170,300,000USD166,800,000USD170,600,000USD161,500,000USD
    Stock Based Compensation34,900,000USD31,700,000USD—29,200,000USD34,100,000USD32,800,000USD27,300,000USD27,000,000USD
    Change To Account Receivables-59,200,000USD-187,900,000USD—9,500,000USD30,900,000USD-170,800,000USD90,900,000USD49,000,000USD
    Change To Inventory-65,100,000USD35,400,000USD—-14,400,000USD-11,900,000USD8,400,000USD-14,600,000USD-25,700,000USD
    Change To Liabilities-35,700,000USD-166,100,000USD—-2,900,000USD18,800,000USD-322,300,000USD——
    Change In Working Capital-130,500,000USD-319,300,000USD———-273,900,000USD——
    Operating Cash Flow445,500,000USD191,500,000USD614,200,000USD387,200,000USD620,600,000USD18,500,000USD777,200,000USD277,300,000USD
    Capital Expenditures-131,600,000USD-121,000,000USD-123,900,000USD-106,700,000USD-77,900,000USD-126,000,000USD-112,100,000USD-115,800,000USD
    Net Investments-10,800,000USD-6,700,000USD——————
    Other Investing Activities-225,700,000USD-202,200,000USD—-374,000,000USD6,900,000USD-53,500,000USD-209,600,000USD-579,100,000USD
    Unclassified Investing Cash Flow1,900,000USD7,800,000USD———-156,500,000USD——
    Investing Cash Flow-366,200,000USD-322,100,000USD—-374,000,000USD-94,100,000USD-336,000,000USD-209,600,000USD-579,100,000USD
    Net Common Stock Issuance-360,100,000USD-137,800,000USD—-25,000,000USD-3,500,000USD-25,500,000USD-75,100,000USD-900,000USD
    Common Dividends Paid-58,700,000USD-61,200,000USD—-59,900,000USD-59,900,000USD-61,600,000USD-60,100,000USD-60,500,000USD
    Other Financing Activities-27,900,000USD-3,400,000USD—-59,500,000USD-267,400,000USD-3,300,000USD-546,700,000USD1,548,300,000USD
    Unclassified Financing Cash Flow-473,200,000USD782,900,000USD———-749,300,000USD——
    Financing Cash Flow-919,900,000USD580,500,000USD—-59,500,000USD-267,400,000USD-839,700,000USD-546,700,000USD1,548,300,000USD
    Effect Of Forex Changes On Cash1,300,000USD-1,100,000USD—-2,900,000USD18,800,000USD7,900,000USD-19,500,000USD5,700,000USD
    Change In Cash-839,300,000USD448,800,000USD—-49,200,000USD277,900,000USD-1,149,300,000USD-19,500,000USD—
    Net Income——164,700,000USD261,100,000USD237,900,000USD—143,400,000USD169,300,000USD
    End Cash Flow——532,300,000USD598,100,000USD647,300,000USD369,400,000USD1,518,700,000USD1,517,300,000USD
    Deferred Income Tax———88,600,000USD-6,100,000USD-6,100,000USD38,500,000USD-19,500,000USD
    Net Debt Issuance———————26,300,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosurePreliminaryDisclosurePreliminaryDisclosureDeterministicFinalDisclosurePreliminaryDisclosurePreliminary

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Depreciation681,100,000USD643,500,000USD577,300,000USD633,900,000USD745,100,000USD624,700,000USD577,200,000USD552,100,000USD
    Stock Based Compensation125,800,000USD116,700,000USD128,700,000USD144,100,000USD153,700,000USD111,700,000USD107,000,000USD91,600,000USD
    Deferred Income Tax97,600,000USD-20,100,000USD-78,100,000USD7,200,000USD-78,000,000USD-47,000,000USD29,200,000USD—
    Change To Account Receivables-125,500,000USD-52,300,000USD-103,800,000USD15,900,000USD222,000,000USD-913,400,000USD-64,100,000USD50,200,000USD
    Change To Inventory-30,200,000USD-12,600,000USD-700,000USD-45,500,000USD2,800,000USD-196,600,000USD-21,900,000USD-18,900,000USD
    Change To Liabilities-383,100,000USD-40,500,000USD-365,600,000USD-252,200,000USD-286,100,000USD252,600,000USD-144,900,000USD37,300,000USD
    Change In Working Capital-199,100,000USD37,100,000USD-67,200,000USD55,900,000USD191,400,000USD-1,072,300,000USD-103,300,000USD-70,300,000USD
    Operating Cash Flow1,640,500,000USD1,585,800,000USD1,327,700,000USD1,955,900,000USD3,109,600,000USD2,135,300,000USD1,444,700,000USD—
    Capital Expenditures-434,500,000USD-489,900,000USD-453,600,000USD-481,900,000USD-460,400,000USD-381,700,000USD-400,200,000USD-379,800,000USD
    Net Investments-192,400,000USD———————
    Other Investing Activities-582,000,000USD-839,000,000USD-671,500,000USD-1,164,000,000USD-496,900,000USD-267,600,000USD-876,000,000USD—
    Unclassified Investing Cash Flow14,900,000USD-37,900,000USD-46,400,000USD-6,300,000USD72,700,000USD6,100,000USD-6,900,000USD265,700,000USD
    Investing Cash Flow-1,194,000,000USD-1,366,800,000USD-1,171,500,000USD-1,652,200,000USD-884,600,000USD-643,200,000USD-1,283,100,000USD—
    Net Debt Issuance-8,800,000USD-11,900,000USD-12,600,000USD-12,300,000USD986,900,000USD-15,200,000USD1,041,100,000USD—
    Net Common Stock Issuance-481,900,000USD-296,500,000USD-1,000,000,000USD-1,100,000,000USD-1,668,500,000USD-100,000,000USD-450,000,000USD—
    Common Dividends Paid-240,700,000USD-243,100,000USD——————
    Other Financing Activities-13,700,000USD-36,700,000USD-19,600,000USD-27,000,000USD-26,600,000USD———
    Unclassified Financing Cash Flow-711,900,000USD1,368,100,000USD972,900,000USD-182,900,000USD-1,357,600,000USD-402,200,000USD-843,800,000USD181,500,000USD
    Financing Cash Flow-1,457,000,000USD779,900,000USD-59,300,000USD-1,322,200,000USD-2,065,800,000USD-517,400,000USD-252,700,000USD—
    Effect Of Forex Changes On Cash24,100,000USD-17,000,000USD9,900,000USD-24,200,000USD-7,300,000USD———
    Change In Cash-986,400,000USD981,900,000USD106,800,000USD-1,042,700,000USD151,900,000USD983,300,000USD—110,200,000USD
    End Cash Flow————1,472,700,000USD———
    Other Non Cash Items—————4,000,000USD4,000,000USD-174,100,000USD
    Net Income———————883,900,000USD
    Total Cash From Operating Activities———————1,305,400,000USD
    Free Cash Flow———————925,600,000USD
    Investments———————-4,000,000USD
    Total Cashflows From Investing Activities———————206,700,000USD
    Net Borrowings———————-409,300,000USD
    Total Cash From Financing Activities———————-1,389,900,000USD
    Dividends Paid———————-467,200,000USD
    Sale Purchase Of Stock———————-700,000,000USD
    Issuance Of Capital Stock———————69,100,000USD
    Begin Period Cash Flow———————316,600,000USD
    End Period Cash Flow———————426,800,000USD
    Exchange Rate Changes———————-12,000,000USD
    Cash And Cash Equivalents Changes———————110,200,000USD
    Other Cashflows From Investing Activities———————324,800,000USD
    Other Cashflows From Financing Activities———————5,100,000USD
    Unclassified Operating Cash Flow———————22,200,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30SegmentBiopharma Laboratory Services836,200,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30SegmentDiagnostics2,900,700,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentBiopharma Laboratory Services780,600,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31SegmentDiagnostics2,762,100,000USDDisclosure
    Q4 2025Quarterly · 2025-12-31SegmentBiopharma Laboratory Services793,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31SegmentDiagnostics2,728,500,000USDLegacy provider
    FY 2025Yearly · 2025-12-31SegmentBiopharma Laboratory Services3,098,200,000USDDisclosure
    FY 2025Yearly · 2025-12-31SegmentDiagnostics10,876,500,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentBiopharma Laboratory Services799,100,000USDDisclosure
    Q3 2025Quarterly · 2025-09-30SegmentDiagnostics2,769,600,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentBiopharma Laboratory Services784,800,000USDDisclosure
    Q2 2025Quarterly · 2025-06-30SegmentDiagnostics2,748,800,000USDDisclosure
    Q1 2025Quarterly · 2025-03-31SegmentBiopharma Laboratory Services721,300,000USDDisclosure
    Q1 2025Quarterly · 2025-03-31SegmentDiagnostics2,629,600,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentBiopharma Laboratory Services767,000,000USDDisclosure
    Q4 2024Quarterly · 2024-12-31SegmentDiagnostics2,586,200,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentBiopharma Laboratory Services2,922,600,000USDDisclosure
    FY 2024Yearly · 2024-12-31SegmentDiagnostics10,144,300,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentDiagnostics2,553,500,000USDDisclosure
    Q3 2024Quarterly · 2024-09-30SegmentDrug Development737,700,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentBiopharma Laboratory Services2,774,200,000USDDisclosure
    FY 2023Yearly · 2023-12-31SegmentDiagnostics9,415,100,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentBiopharma Laboratory Services2,697,300,000USDDisclosure
    FY 2022Yearly · 2022-12-31SegmentDiagnostics9,203,500,000USDDisclosure
    FY 2021Yearly · 2021-12-31SegmentDiagnostics10,363,600,000USDDisclosure
    FY 2021Yearly · 2021-12-31SegmentDrug Development2,860,700,000USDDisclosure
    FY 2021Yearly · 2021-12-31GeographyEurope2,050,800,000USDDisclosure
    FY 2021Yearly · 2021-12-31GeographyNorth America13,093,700,000USDDisclosure
    FY 2021Yearly · 2021-12-31GeographyOthercountries976,400,000USDDisclosure
    FY 2020Yearly · 2020-12-31GeographyEurope1,512,200,000USDDisclosure
    FY 2020Yearly · 2020-12-31GeographyNorth America11,525,300,000USDDisclosure
    FY 2020Yearly · 2020-12-31GeographyOthercountries941,000,000USDDisclosure
    FY 2019Yearly · 2019-12-31SegmentDiagnostics7,000,100,000USDDisclosure
    FY 2019Yearly · 2019-12-31SegmentDrug Development4,578,100,000USDDisclosure
    FY 2019Yearly · 2019-12-31GeographyCanada333,300,000USDDisclosure
    FY 2019Yearly · 2019-12-31GeographyCH532,900,000USDDisclosure
    FY 2019Yearly · 2019-12-31GeographyOthercountries1,199,700,000USDDisclosure
    FY 2019Yearly · 2019-12-31GeographyUnited Kingdom507,900,000USDDisclosure
    FY 2019Yearly · 2019-12-31GeographyUnited States8,981,000,000USDDisclosure
    FY 2018Yearly · 2018-12-31SegmentCovance Drug Development4,313,100,000USDDisclosure
    FY 2018Yearly · 2018-12-31SegmentLab Corp Diagnostics7,030,800,000USDDisclosure
    FY 2018Yearly · 2018-12-31GeographyCanada342,200,000USD0000920148-19-000033
    FY 2018Yearly · 2018-12-31GeographyCH527,400,000USD0000920148-19-000033
    FY 2018Yearly · 2018-12-31GeographyOthercountries1,181,400,000USD0000920148-19-000033
    FY 2018Yearly · 2018-12-31GeographyUnited Kingdom438,900,000USD0000920148-19-000033
    FY 2018Yearly · 2018-12-31GeographyUnited States8,843,500,000USD0000920148-19-000033
    FY 2017Yearly · 2017-12-31SegmentCovance Drug Development3,451,600,000USDDisclosure
    FY 2017Yearly · 2017-12-31SegmentLab Corp Diagnostics6,858,200,000USDDisclosure
    FY 2017Yearly · 2017-12-31GeographyCanada327,800,000USD0000920148-18-000024
    FY 2017Yearly · 2017-12-31GeographyCH484,400,000USD0000920148-18-000024
    FY 2017Yearly · 2017-12-31GeographyOthercountries857,700,000USD0000920148-18-000024
    FY 2017Yearly · 2017-12-31GeographyUnited Kingdom302,000,000USD0000920148-18-000024
    FY 2017Yearly · 2017-12-31GeographyUnited States8,234,000,000USD0000920148-18-000024
    FY 2016Yearly · 2016-12-31GeographyCanada295,800,000USD0000920148-17-000018
    FY 2016Yearly · 2016-12-31GeographyCH450,500,000USD0000920148-17-000018
    FY 2016Yearly · 2016-12-31GeographyOthercountries774,500,000USD0000920148-17-000018
    FY 2016Yearly · 2016-12-31GeographyUnited Kingdom275,900,000USD0000920148-17-000018
    FY 2016Yearly · 2016-12-31GeographyUnited States7,640,500,000USD0000920148-17-000018
    FY 2015Yearly · 2015-12-31GeographyCanada290,400,000USD0000920148-16-000162
    FY 2015Yearly · 2015-12-31GeographyCH359,700,000USD0000920148-16-000162
    FY 2015Yearly · 2015-12-31GeographyOthercountries570,600,000USD0000920148-16-000162
    FY 2015Yearly · 2015-12-31GeographyUnited Kingdom281,700,000USD0000920148-16-000162
    FY 2015Yearly · 2015-12-31GeographyUnited States7,003,300,000USD0000920148-16-000162

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.